COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Executive Insights Life Sciences & Pharma Key Indicators of a Successful Biopharmaceutical Product Launch December 20, 2022
Article Mental and Behavioral Health A Test of Resilience: Looking Forward to Psychedelics Funding in 2023 March 7, 2023
Video / Webinar Biotech and Pharmaceuticals Launch Excellence for Biopharma: Planning for Success March 8, 2023
Executive Insights Life Sciences & Pharma Looking Ahead in Pharma Services: Key Trends Impacting the Industry April 14, 2022
Article MedTech APAC Hospital Priorities 2022: Strategic Implications for Medtech Firms April 14, 2022